Who are Trastuzumab Injectable Solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trastuzumab + Pertuzumab, Herceptin Hylecta®, Pertuzumab and Trastuzumab, trastuzumab (H), Pertuzumab + trastuzumab, CT-P55.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trastuzumab-injectable-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Trastuzumab Injectable Solution — Competitive Intelligence Brief

Trastuzumab Injectable Solution (Trastuzumab Injectable Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2-targeted monoclonal antibody. Area: Oncology.

phase 3 HER2-targeted monoclonal antibody HER2 (human epidermal growth factor receptor 2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Trastuzumab Injectable Solution (Trastuzumab Injectable Solution) — Spanish Breast Cancer Research Group. Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Trastuzumab Injectable Solution TARGET	Trastuzumab Injectable Solution	Spanish Breast Cancer Research Group	phase 3	HER2-targeted monoclonal antibody	HER2 (human epidermal growth factor receptor 2)
Trastuzumab + Pertuzumab	Trastuzumab + Pertuzumab	Massachusetts General Hospital	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Herceptin Hylecta®	Herceptin Hylecta®	Biocon Biologics UK PLC	marketed	HER2-targeted monoclonal antibody	HER2 (human epidermal growth factor receptor 2)
Pertuzumab and Trastuzumab	Pertuzumab and Trastuzumab	QuantumLeap Healthcare Collaborative	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
trastuzumab (H)	trastuzumab (H)	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	marketed	HER2-targeted monoclonal antibody	HER2 (human epidermal growth factor receptor 2)
Pertuzumab + trastuzumab	Pertuzumab + trastuzumab	European Organisation for Research and Treatment of Cancer - EORTC	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
CT-P55	CT-P55	Celltrion	phase 3	HER2-targeted monoclonal antibody (trastuzumab biosimilar)	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2-targeted monoclonal antibody class)

Spanish Breast Cancer Research Group · 3 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Samsung Bioepis Co., Ltd. · 1 drug in this class
Biocon Biologics UK PLC · 1 drug in this class
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class
Tanvex BioPharma USA, Inc. · 1 drug in this class
Zydus Lifesciences Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trastuzumab Injectable Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-injectable-solution. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab